Outcomes in COVID-19 bebtelovimab studies
Outcomes in bebtelovimab studies.
Efficacy is variant dependent. In Vitro research suggests a lack of efficacy for omicron BQ.1.1 Planas mAb use may create new variants that spread globally
Focosi . mAb use with variants can be associated with prolonged viral loads, clinical deterioration, and immune escape
Choudhary .
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+ Lilly (RCT) -151% 2.51 [0.10-61.1] death 1/252 0/128 Improvement, RR [CI] Treatment Control BLAZE-4 Dougan (RCT) -27% 1.27 [0.25-6.46] hosp. 5/252 2/128 Dryden-Peterson 86% 0.14 [0.01-2.76] death 0/377 3/377 Kip 20% 0.80 [0.32-2.02] death/hosp. 6/157 15/314 Molina (PSM) 57% 0.43 [0.11-1.30] death 3/3,739 11/5,423 Sridhara (PSM) 86% 0.14 [0.01-2.76] death 0/1,091 3/1,091 Tau2 = 0.00, I2 = 0.0%, p = 0.2 Early treatment 34% 0.66 [0.35-1.24] 15/5,868 34/7,461 34% lower risk All studies 34% 0.66 [0.35-1.24] 15/5,868 34/7,461 34% lower risk 6 bebtelovimab COVID-19 studies c19 earlyTau2 = 0.00, I2 = 0.0%, p = 0.2 Effect extraction pre-specified (most serious outcome) Favors bebtelovimab Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+ Lilly (RCT) -151% 2.51 [0.10-61.1] 1/252 0/128 Improvement, RR [CI] Treatment Control Dryden-Peterson 86% 0.14 [0.01-2.76] 0/377 3/377 Molina (PSM) 57% 0.43 [0.11-1.30] 3/3,739 11/5,423 Sridhara (PSM) 86% 0.14 [0.01-2.76] 0/1,091 3/1,091 Tau2 = 0.00, I2 = 0.0%, p = 0.078 Early treatment 60% 0.40 [0.14-1.11] 4/5,459 17/7,019 60% lower risk All studies 60% 0.40 [0.14-1.11] 4/5,459 17/7,019 60% lower risk 4 bebtelovimab COVID-19 mortality results c19 earlyTau2 = 0.00, I2 = 0.0%, p = 0.078 Favors bebtelovimab Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+ Molina 59% 0.41 [0.17-1.03] 6/3,739 21/5,423 Improvement, RR [CI] Treatment Control Tau2 = 0.00, I2 = 0.0%, p = 0.056 Early treatment 59% 0.41 [0.17-1.03] 6/3,739 21/5,423 59% lower risk All studies 59% 0.41 [0.17-1.03] 6/3,739 21/5,423 59% lower risk 1 bebtelovimab COVID-19 ICU result c19 earlyTau2 = 0.00, I2 = 0.0%, p = 0.056 Favors bebtelovimab Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+ Lilly (RCT) -27% 1.27 [0.25-6.46] hosp. 5/252 2/128 Improvement, RR [CI] Treatment Control BLAZE-4 Dougan (RCT) -27% 1.27 [0.25-6.46] hosp. 5/252 2/128 Dryden-Peterson 29% 0.71 [0.32-1.59] hosp. 10/377 14/377 Molina (PSM) 56% 0.44 [0.30-0.64] hosp. 38/3,739 107/5,423 Sridhara (PSM) 11% 0.89 [0.52-1.53] hosp. 24/1,091 27/1,091 Tau2 = 0.08, I2 = 37.2%, p = 0.065 Early treatment 33% 0.67 [0.44-1.03] 82/5,711 152/7,147 33% lower risk All studies 33% 0.67 [0.44-1.03] 82/5,711 152/7,147 33% lower risk 5 bebtelovimab COVID-19 hospitalization results c19 earlyTau2 = 0.08, I2 = 37.2%, p = 0.065 Favors bebtelovimab Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+ Lilly (RCT) -151% 2.51 [0.10-61.1] death 1/252 0/128 Improvement, RR [CI] Treatment Control BLAZE-4 Dougan (RCT) -27% 1.27 [0.25-6.46] hosp. 5/252 2/128 Dryden-Peterson 86% 0.14 [0.01-2.76] death 0/377 3/377 Kip 20% 0.80 [0.32-2.02] death/hosp. 6/157 15/314 Molina (PSM) 57% 0.43 [0.11-1.30] death 3/3,739 11/5,423 Sridhara (PSM) 86% 0.14 [0.01-2.76] death 0/1,091 3/1,091 Tau2 = 0.00, I2 = 0.0%, p = 0.2 Early treatment 34% 0.66 [0.35-1.24] 15/5,868 34/7,461 34% lower risk All studies 34% 0.66 [0.35-1.24] 15/5,868 34/7,461 34% lower risk 6 bebtelovimab COVID-19 serious outcomes c19 earlyTau2 = 0.00, I2 = 0.0%, p = 0.2 Effect extraction pre-specified (most serious outcome) Favors bebtelovimab Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+ Lilly (RCT) 36% 0.64 [0.40-1.03] viral+ 33/252 26/128 Improvement, RR [CI] Treatment Control BLAZE-4 Dougan (RCT) 4% 0.96 [0.95-0.97] viral load 125 (n) 128 (n) Tau2 = 0.05, I2 = 64.1%, p = 0.37 Early treatment 15% 0.85 [0.59-1.22] 33/377 26/256 15% lower risk All studies 15% 0.85 [0.59-1.22] 33/377 26/256 15% lower risk 2 bebtelovimab COVID-19 viral clearance results c19 earlyTau2 = 0.05, I2 = 64.1%, p = 0.37 Favors bebtelovimab Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+ Lilly (RCT) -151% 2.51 [0.10-61.1] death 1/252 0/128 Improvement, RR [CI] Treatment Control BLAZE-4 Dougan (RCT) -27% 1.27 [0.25-6.46] hosp. 5/252 2/128 Tau2 = 0.00, I2 = 0.0%, p = 0.62 Early treatment -46% 1.46 [0.34-6.22] 6/504 2/256 46% higher risk All studies -46% 1.46 [0.34-6.22] 6/504 2/256 46% higher risk 2 bebtelovimab COVID-19 Randomized Controlled Trials c19 earlyTau2 = 0.00, I2 = 0.0%, p = 0.62 Effect extraction pre-specified (most serious outcome) Favors bebtelovimab Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+ Lilly (RCT) -151% 2.51 [0.10-61.1] 1/252 0/128 Improvement, RR [CI] Treatment Control Tau2 = 0.00, I2 = 0.0%, p = 0.58 Early treatment -151% 2.51 [0.10-61.1] 1/252 0/128 151% higher risk All studies -151% 2.51 [0.10-61.1] 1/252 0/128 151% higher risk 1 bebtelovimab COVID-19 RCT mortality result c19 earlyTau2 = 0.00, I2 = 0.0%, p = 0.58 Favors bebtelovimab Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+ Dryden-Peterson 86% 0.14 [0.01-2.76] death 0/377 3/377 Improvement, RR [CI] Treatment Control Kip 20% 0.80 [0.32-2.02] death/hosp. 6/157 15/314 Molina (PSM) 57% 0.43 [0.11-1.30] death 3/3,739 11/5,423 Sridhara (PSM) 86% 0.14 [0.01-2.76] death 0/1,091 3/1,091 Tau2 = 0.00, I2 = 0.0%, p = 0.091 Early treatment 46% 0.54 [0.27-1.10] 9/5,364 32/7,205 46% lower risk All studies 46% 0.54 [0.27-1.10] 9/5,364 32/7,205 46% lower risk 4 bebtelovimab COVID-19 peer reviewed studies c19 earlyTau2 = 0.00, I2 = 0.0%, p = 0.091 Effect extraction pre-specified (most serious outcome) Favors bebtelovimab Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+ Lilly (RCT) -151% 2.51 [0.10-61.1] death 1/252 0/128 Improvement, RR [CI] Treatment Control Lilly (RCT) -201% 3.01 [0.12-73.2] death 1/127 0/128 Lilly (RCT) -27% 1.27 [0.25-6.46] hosp. 5/252 2/128 Lilly (RCT) -51% 1.51 [0.26-8.90] hosp. 3/127 2/128 Lilly (RCT) -2% 1.02 [0.15-7.16] hosp. 2/125 2/128 Lilly (RCT) 36% 0.64 [0.40-1.03] viral+ 33/252 26/128 Lilly (RCT) 38% 0.62 [0.35-1.10] viral+ 16/127 26/128 Lilly (RCT) 33% 0.67 [0.38-1.17] viral+ 17/125 26/128 BLAZE-4 Dougan (RCT) -27% 1.27 [0.25-6.46] hosp. 5/252 2/128 BLAZE-4 Dougan (RCT) -2% 1.02 [0.15-7.16] hosp. 2/125 2/128 BLAZE-4 Dougan (RCT) 4% 0.96 [0.95-0.97] viral load 125 (n) 128 (n) BLAZE-4 Dougan (RCT) 30% 0.70 [0.63-0.78] viral load 125 (n) 128 (n) BLAZE-4 Dougan (RCT) 15% 0.85 [0.81-0.88] viral load 125 (n) 128 (n) BLAZE-4 Dougan (RCT) 39% 0.61 [0.34-1.11] viral+ 15/125 25/128 Dryden-Peterson 86% 0.14 [0.01-2.76] death 0/377 3/377 Dryden-Peterson 43% 0.57 [0.28-1.19] death/hosp. 10/377 17/377 Dryden-Peterson 29% 0.71 [0.32-1.59] hosp. 10/377 14/377 Kip 20% 0.80 [0.32-2.02] death/hosp. 6/157 15/314 Molina (PSM) 57% 0.43 [0.11-1.30] death 3/3,739 11/5,423 Molina 59% 0.41 [0.17-1.03] ICU 6/3,739 21/5,423 Molina (PSM) 56% 0.44 [0.30-0.64] hosp. 38/3,739 107/5,423 Molina (PSM) 46% 0.54 [0.38-0.74] hosp. 48/3,739 116/5,423 Molina (PSM) -33% 1.33 [1.12-1.57] progression 260/3,739 275/5,423 Sridhara (PSM) 86% 0.14 [0.01-2.76] death 0/1,091 3/1,091 Sridhara (PSM) 25% 0.75 [0.43-1.31] death/hosp. 24/1,091 28/1,091 Sridhara (PSM) 11% 0.89 [0.52-1.53] hosp. 24/1,091 27/1,091 Bebtelovimab COVID-19 outcomes c19 earlyFavors bebtelovimab Favors control
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation.
FLCCC and
WCH
provide treatment protocols.
Thanks for your feedback! Please search before submitting papers and note
that studies are listed under the date they were first available, which may be
the date of an earlier preprint.
Submit
